


-109-  
CLAIMS

What is claimed is:

1. A compound of the formula:




5

wherein:

X is NH, O or S;

10 R<sub>1</sub> is selected from halogen, -C=CH<sub>2</sub>, -O-C<sub>1</sub>-C<sub>6</sub> alkyl, -C=CH-(CH<sub>2</sub>)<sub>m</sub>-O-C<sub>1</sub>-C<sub>6</sub> alkyl, -C=C-(CH<sub>2</sub>)<sub>m</sub>-O-C<sub>1</sub>-C<sub>6</sub> alkyl, -C=C-(CH<sub>2</sub>)<sub>m</sub>-NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -C≡CH, -C≡C-(CH<sub>2</sub>)<sub>m</sub>-OH, C≡C-(CH<sub>2</sub>)<sub>m</sub>-NH<sub>2</sub>, -COOH, -(CH<sub>2</sub>)<sub>m</sub>-COOH, -CONH<sub>2</sub>, -COO-C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)<sub>m</sub>-CONH<sub>2</sub>, -C(O)(C<sub>1</sub>-C<sub>6</sub> alkyl), -C(O)NHSO<sub>2</sub>H, -(CH<sub>2</sub>)<sub>m</sub>-C(O)NHSO<sub>2</sub>H, -C(O)NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub> alkyl), -(CH<sub>2</sub>)<sub>m</sub>-C(O)NHSO<sub>2</sub>-(C<sub>1</sub>-C<sub>3</sub> alkyl), or C<sub>1</sub>-C<sub>6</sub> alkyl, -S-C<sub>1</sub>-C<sub>6</sub> alkyl or alkenyl, with the alkyl, -S-alkyl and alkenyl chains in each of these R<sub>1</sub> moieties being optionally substituted by from 1 to 3 OH groups and/or by from 1 to 5 fluorine atoms;

20 R<sub>2</sub> is -R<sub>3</sub>, -O-R<sub>3</sub>, -S-R<sub>3</sub> or a moiety selected from the group of NH<sub>2</sub>, NHR<sub>3</sub>, N(C<sub>1</sub>-C<sub>3</sub> alkyl)-R<sub>3</sub>, -NH-(CH<sub>2</sub>)<sub>n</sub>-O-(C<sub>1</sub>-C<sub>3</sub> alkyl), -NH-(CH<sub>2</sub>)<sub>n</sub>-O-C(O)-(C<sub>1</sub>-C<sub>3</sub> alkyl) or -N((CH<sub>2</sub>)<sub>n</sub>-O-(C<sub>1</sub>-C<sub>3</sub> alkyl))<sub>2</sub>, or a moiety selected from the group of:



R<sub>3</sub> is a moiety selected from:

5

a) C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkenyl, the alkyl and alkenyl groups each being optionally substituted by from 1 to 4 OH or halogen groups;


10

b) -(CH<sub>2</sub>)<sub>n</sub>-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>-NH(C<sub>1</sub>-C<sub>3</sub> alkyl), -(CH<sub>2</sub>)<sub>n</sub>-N(C<sub>1</sub>-C<sub>3</sub> alkyl)<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>-O-(C<sub>1</sub>-C<sub>3</sub> alkyl), -(CH<sub>2</sub>)<sub>m</sub>-C(O)-O-(C<sub>1</sub>-C<sub>3</sub> alkyl), or (CH<sub>2</sub>)<sub>n</sub>-N(C<sub>1</sub>-C<sub>3</sub> alkyl)-C(O)-(C<sub>1</sub>-C<sub>3</sub> alkyl);

15


c) phenyl, -(CH<sub>2</sub>)<sub>m</sub>-phenyl, -(CH<sub>2</sub>)<sub>m</sub>-O-phenyl, the phenyl ring of each being optionally substituted by 1 or 2 groups selected from C<sub>1</sub>-C<sub>3</sub> alkoxy, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>3</sub> alkyl), N(C<sub>1</sub>-C<sub>3</sub> alkyl)<sub>2</sub>; or

d) a moiety selected from the group of:




- 5  $R_4$  is selected from H or  $C_1$ - $C_3$  alkyl, optionally substituted by OH;  
 $R_5$  is selected from H or halogen;  
 $R_6$  is selected from H or F;  
 $R_7$  is selected from F,  $CH_2F$ ,  $CHF_2$ , or  $-CF_3$ ;  
n in each instance is independently selected as an integer of from 1 to 6
- 10 m in each instance is independently selected as an integer of from 1 to 4;  
or a pharmaceutically acceptable salt or ester form thereof.

2. A compound of Claim 1 of the formula:



wherein:

- 5                     $R_1$  is selected from I, Br or  $C_1$ - $C_3$  alkyl;  
                       $R_2$  is  $R_3$ ,  $-O-R_3$ ,  $-S-R_3$  or a moiety selected from the group of  $NH_2$ ,  $NHR_3$ ,  
                       $N(C_1-C_3 \text{ alkyl})-R_3$ ,  $-NH-(CH_2)_n-O-(C_1-C_3 \text{ alkyl})$ ,  $-NH-(CH_2)_n-O-C(O)-(C_1-C_3$   
                      alkyl) or  $-N((CH_2)_n-O-(C_1-C_3 \text{ alkyl}))_2$ ;
- 10                    $R_3$  is a moiety selected from:
- a)         $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkenyl, the alkyl and alkenyl groups  
                      each being optionally substituted by from 1 to 4 OH groups;
- b)         $-(CH_2)_n-NH_2$ ,  $-(CH_2)_n-NH(C_1-C_3 \text{ alkyl})$ ,  $-(CH_2)_n-N(C_1-C_3$   
15                   alkyl) $_2$ ,  $-(CH_2)_n-O-(C_1-C_3 \text{ alkyl})$ ,  $-(CH_2)_m-C(O)-O-(C_1-C_3 \text{ alkyl})$ ,
- c)        phenyl,  $-(CH_2)_m$ -phenyl,  $-(CH_2)_m$ -O-phenyl, the phenyl  
                      ring of each being optionally substituted by 1 or 2 groups selected from  
                       $C_1$ - $C_3$  alkoxy,  $NH_2$ ,  $NH(C_1-C_3 \text{ alkyl})$ ,  $N(C_1-C_3 \text{ alkyl})_2$  ; or
- 20                        d)        a moiety selected from the group of:



5  $R_4$  is selected from H or  $C_1$ - $C_3$  alkyl, optionally substituted by OH;

$n$  is an integer of from 1 to 6

$m$  is an integer of from 1 to 4;

or a pharmaceutically acceptable salt form thereof.

10 3. A compound of Claim 1 selected from the group of:

5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamine;

5-[5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamine;

15 5-[2-(4-Bromo-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-  
[1,3,4]oxadiazol-2-ylamine;

- { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-ethyl-amine;  
Allyl-{ 5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-amine;  
5 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2,4-dimethoxy-phenyl)-amine;  
*N*-(5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl)-*N*',*N*'-dimethyl-benzene-1,4-diamine;  
3-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino}-propane-1,2-diol;  
10 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(3-morpholin-4-yl-propyl)-amine  
hydrochloride salt;  
*N*-(5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl)-*N*',*N*'-diethyl-propane-1,3-diamine;  
15 or a pharmaceutically acceptable salt form thereof.
4. A compound of Claim 1 selected from the group of:
- N*'1'-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-ethane-1,2-diamine as a trifluoro-acetic  
20 acid;  
*N*-(5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl)-*N*',*N*',*N*'-trimethyl-propane-1,3-diamine;  
{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-piperidin-1-yl-ethyl)-amine;  
25 *N*'1'-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-butane-1,4-diamine;  
*N*'1'-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-propane-1,3-diamine;  
30 *N*-(5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl)-*N*',*N*'-dimethyl-propane-1,3-diamine;  
*N*-(5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl)-*N*',*N*'-dimethyl-ethane-1,2-diamine;

*N*-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-*N'*-methyl-ethane-1,2-diamine;  
*N*-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-2,2,*N'*,*N'*-tetramethyl-propane-1,3-diamine;  
5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(3-methoxy-propyl)-amine;  
or a pharmaceutically acceptable salt form thereof.

5. A compound of Claim 1 selected from the group of:
- 10 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;  
(2,3-Difluoro-6-{5-[4-(2-methoxy-ethyl)-piperazin-1-yl]-[1,3,4]oxadiazol-  
2-yl}-phenyl)-(2-fluoro-4-iodo-phenyl)-amine;  
5-5-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
15 [1,3,4]oxadiazol-2-ylamino}-2,2-dimethyl-pentan-1-ol;  
1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-pyrrolidin-3-ol;  
(1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-piperidin-4-yl)-methanol;  
20 2-(1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-piperidin-4-yl)-ethanol;  
4-({5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-ethyl-amino)-butan-1-ol;  
1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
25 [1,3,4]oxadiazol-2-yl}-piperidin-4-ol  
2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino}-ethanol;  
3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino}-propan-1-ol;  
30 or a pharmaceutically acceptable salt form thereof.

6. A compound of Claim 1 selected from the group of:

- 4-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino}-butan-1-ol;  
5-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino}-pentan-1-ol;  
5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-methoxy-ethyl)-amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-phenoxy-ethyl)-amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-pyridin-4-yl-ethyl)-amine;  
10 Butyl-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(5-methyl-furan-2-ylmethyl)-amine;  
15 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-(2-thiophen-2-yl-ethyl)-amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-[2-(3-methoxy-phenyl)-ethyl]-amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-[2-(3,4-dimethoxy-phenyl)-ethyl]-amine;  
20 or a pharmaceutically acceptable salt form thereof.
7. A compound of Claim 1 selected from the group of:
- {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-[2-(2,5-dimethoxy-phenyl)-ethyl]-amine;  
25 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-  
amine;  
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-methyl-(2-pyridin-4-yl-ethyl)-amine;  
30 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl}-methyl-(2-pyridin-2-yl-ethyl)-amine;



- { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-propyl-amine;  
sec-Butyl-{ 5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-amine;
- 5 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(2,2-dimethyl-propyl)-amine;  
{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-isobutyl-amine;
- 10 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(1,2,2-trimethyl-propyl)-amine;  
{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(2-methyl-butyl)-amine;  
or a pharmaceutically acceptable salt form thereof.
- 15 8. A compound of Claim 1 selected from the group of:  
Bicyclo[2.2.1]hept-2-yl-{ 5-[3,4-difluoro-2-(2-fluoro-4-iodo-  
phenylamino)-phenyl]-[1,3,4]oxadiazol-2-yl }-amine;  
{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-[2-(1-methyl-1H-pyrrol-2-yl)-ethyl]-amine;
- 20 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-[2-(1-methyl-1H-imidazol-4-yl)-ethyl]-  
amine;
- { 2,3-Difluoro-6-[5-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-  
[1,3,4]oxadiazol-2-yl]-phenyl }-(2-fluoro-4-iodo-phenyl)-amine;
- 25 { 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(2-methoxy-1-methyl-ethyl)-amine;  
{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(3-ethoxy-propyl)-amine;
- 30 3-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino }-dihydro-furan-2-one;  
3-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-ylamino }-propionic acid;

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-[2-(2,6-dimethyl-phenoxy)-1-methyl-ethyl]-  
amine;

(1-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-pyrrolidin-3-yl)-diethyl-amine;  
or a pharmaceutically acceptable salt or ester form thereof.

5

9. A compound of Claim 1 selected from the group of:

{ 2,3-Difluoro-6-[5-(4-methyl-[1,4]diazepan-1-yl)-[1,3,4]oxadiazol-2-yl]-  
phenyl }-(2-fluoro-4-iodo-phenyl)-amine;

10

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amine;

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(4-pyrrolidin-1-yl-butyl)-amine;

15

N\*4\*-{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-N\*1\*,N\*1\*-diethyl-pentane-1,4-diamine;

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(tetrahydro-furan-2-ylmethyl)-amine;

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]oxadiazol-2-yl }-bis-(2-methoxy-ethyl)-amine;

20

N-{ 5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-  
[1,3,4]oxadiazol-2-yl }-N'-methyl-ethane-1,2-diamine;

{ 5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-  
[1,3,4]oxadiazol-2-yl }-(2-morpholin-4-yl-ethyl)-amine;

25

2-{ 5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-  
[1,3,4]oxadiazol-2-ylamino }-ethanol;

Allyl-{ 5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-  
[1,3,4]oxadiazol-2-yl }-amine;

or a pharmaceutically acceptable salt form thereof.

30

10. A compound of Claim 1 selected from the group of:

{ 5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-  
[1,3,4]thiadiazol-2-yl }-ethyl-amine;

- {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-pyrrolidin-1-yl-propyl)-amine;  
N<sup>1</sup>,N<sup>1</sup>-Diethyl-N2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-ethane-1,2-diamine;  
5 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-isopropyl-amine;  
[2,3-Difluoro-6-(5-pyrrolidin-1-yl-1,3,4-oxadiazol-2-yl)-phenyl]-(4-ethyl-2-fluoro-phenyl)-amine;  
N<sup>1</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N>3\_-methyl-propane-1,3-diamine;  
10 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-furan-2-ylmethyl-amine;  
(2,2-Dimethoxy-ethyl)-{5-[2-(ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;  
15 {2,3-Difluoro-6-[5-(4-phenyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-methoxy-ethyl)-amine;  
or a pharmaceutically acceptable salt form thereof.  
20
11. A compound of Claim 1 selected from the group of:  
6-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-hexanenitrile;  
(3,3-Diethoxy-propyl)-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;  
25 Diallyl-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-methylsulfanyl-propyl)-amine;  
30 4-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-isoxazolidin-3-one;  
N<sup>1</sup>-Ethyl-N<sup>1</sup>-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N<sup>2</sup>,N<sup>2</sup>-dimethyl-ethane-1,2-diamine;

{2,3-Difluoro-6-[5-(4-methyl-perhydro-1,4-diazepin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
 1-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-piperidine-3-carboxylic acid diethylamide;  
 5 N-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-O-(tetrahydro-pyran-2-yl)-hydroxylamine;  
 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-morpholin-4-yl-propyl)-amine;  
 or a pharmaceutically acceptable salt form thereof.

10

12. A compound of Claim 1 selected from the group of:

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(4H-1,2,4-triazol-3-yl)-amine;  
 N<sup>1</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N2-methyl-ethane-1,2-diamine;  
 15 N<sup>1</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N1,N>3\_,N>3\_-trimethyl-propane-1,3-diamine;  
 {2,3-Difluoro-6-[5-(4-pyridin-2-yl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
 20 N<sup>2</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N1,N1-dimethyl-propane-1,2-diamine;  
 N<sup>1</sup>-(3-Dimethylamino-propyl)-N<sup>1</sup>-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N>3\_,N>3\_-dimethyl-propane-1,3-diamine;  
 25 N<sup>1</sup>-Cyclohexyl-N>3\_-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-propane-1,3-diamine;  
 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-phenoxy-ethyl)-amine;  
 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;  
 30 Cyclopropylmethyl-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-propyl-amine;  
 or a pharmaceutically acceptable salt form thereof.

13. A compound of Claim 1 selected from the group of:
- (4-Ethyl-2-fluoro-phenyl)-{6-[5-(4-ethyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-2,3-difluoro-phenyl}-amine;
- 5 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(1-methyl-pyrrolidin-3-yl)-amine;
- N<sup>1</sup>,N<sup>1</sup>-Diethyl-N2-(2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-ethyl)-ethane-1,2-diamine;
- 10 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-thiophen-2-ylmethyl-amine;
- {2,3-Difluoro-6-[5-(4-pyrrolidin-1-yl-piperidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
- {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(tetrahydro-pyran-2-ylmethyl)-amine;
- 15 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-4-yl-ethyl)-amine;
- {6-[5-(4-Benzyl-perhydro-1,4-diazepin-1-yl)-1,3,4-oxadiazol-2-yl]-2,3-difluoro-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
- {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-2-ylmethyl-amine;
- 20 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(5-methyl-furan-2-ylmethyl)-amine;
- or a pharmaceutically acceptable salt form thereof.
- 25 14. A compound of Claim 1 selected from the group of:
- (2-Ethoxy-benzyl)-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;
- {2,3-Difluoro-6-[5-(4-methyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
- 30 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-3-ylmethyl-amine;
- {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-thiophen-2-yl-ethyl)-amine;

- {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-3-yl-ethyl)-amine;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-4-ylmethyl-amine;  
5 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-2-yl-ethyl)-amine;  
N-(2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-ethyl)-acetamide;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(6-methoxy-pyridin-3-yl)-amine;  
10 {2,3-Difluoro-6-[5-(2-pyridin-4-yl-pyrrolidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
or a pharmaceutically acceptable salt form thereof.
- 15 15. A compound of Claim 1 selected from the group of:  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-methanesulfonyl-ethyl)-methyl-amine;  
N<sup>2</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N<sup>1</sup>,N<sup>1</sup>-dimethyl-1-phenyl-ethane-1,2-diamine;  
20 {2,3-Difluoro-6-[5-(4-pyridin-2-ylmethyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-1-phenyl-ethyl)-amine;  
{2,3-Difluoro-6-[5-(3-pyridin-4-yl-pyrrolidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;  
25 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(2-pyridin-4-yl-ethyl)-amine;  
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(2-pyridin-2-yl-ethyl)-amine;  
30 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-2-pyridin-3-yl-ethyl)-amine;  
N<sup>1</sup>-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N<sup>2</sup>,N<sup>2</sup>-dimethyl-1-phenyl-ethane-1,2-diamine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-imidazol-1-yl-propyl)-amine;  
or a pharmaceutically acceptable salt form thereof.

- 5        16.    A compound of Claim 1 selected from the group of:  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(tetrahydro-pyran-2-ylmethyl)-amine;  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-furan-2-yl-ethyl)-amine;  
10        {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-thiophen-2-yl-thiazol-4-ylmethyl)-amine;  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(5-methyl-isoxazol-3-ylmethyl)-amine;  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-[2-(4-methyl-1H-imidazol-2-yl)-ethyl]-amine;  
15        {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-[2-(5-pyridin-4-yl-2H-1,2,4-triazol-3-yl)-ethyl]-amine;  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(1-methyl-2-thiophen-3-yl-ethyl)-amine;  
20        {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(1H-tetrazol-5-ylmethyl)-amine;  
             {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-phenyl-1H-pyrazol-4-ylmethyl)-amine; or  
25        2-{5-[2-(4-ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethanol  
             or a pharmaceutically acceptable salt form thereof.
17.    A compound of Claim 1 selected from the group of:  
30        [2,3-Difluoro-6-(5-methyl-4H-[1,2,4]triazol-3-yl)-phenyl]-(4-ethyl-2-fluoro-phenyl)-amine;  
             (4-Ethyl-2-fluoro-phenyl)-[6-(5-ethyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-amine;

- [6-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(2-fluoro-4-iodo-phenyl)-amine;
- [6-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(4-ethynyl-2-fluoro-phenyl)-amine;
- 5 {6-[5-(3-Bromo-propyl)-[1,3,4]oxadiazol-2-yl]-2,3-difluoro-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
- {2,3-Difluoro-6-[5-(3-morpholin-4-yl-propyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
- 3-(4-{2,3-Difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-propan-1-ol;
- 10 {5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;
- 1-(4-{2,3-Difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanone;
- 15 3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2 (R)-diol;
- 3-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;
- 3-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;
- 20 3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2 (S)-diol;
- 2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol
- 25 2-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;
- {5-[3,4-Difluoro-2-(2-fluoro-4-vinyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;
- 2-(4-{2,3-difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanol;
- 30 2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylsulfanyl}-ethanol;



- [6-(5-Allylsulfanyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(2-fluoro-4-iodo-phenyl)-amine;  
2-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;  
5 2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;  
3-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;  
3-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;  
10 3-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;  
3-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;  
15 2-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethanol;  
2-(4-{2,3-difluoro-6-[5-(2-methylamino-ethylamino)-1[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanol; or  
N-(2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethyl)-N-methyl-acetamide;  
20 Acetic acid 2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethyl ester  
or a pharmaceutically acceptable salt form thereof.
- 25 18. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or ester form thereof, and a pharmaceutically acceptable carrier.
- 30 19. A method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Claim 1.

20. A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.
- 5 21. A method of Claim 19 wherein the cancer is brain, breast, lung, ovarian, pancreatic, prostate, renal, or colorectal cancer.
22. A method of treating neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a  
10 compound of Claim 1.
23. A method of treating chronic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of  
15 Claim 1.